title: [Successful prevention of Pneumocystis carinii infection with 1,920 mg of trimethoprim-sulfamethoxazole daily in patients with malignant hematopoietic diseases].
abstract: During 1991-94 we treated 51 patients with acute myeloid leukaemias and 3 patients with a myelodysplastic syndrome of refractory anaemia with excess of blasts in transformation. The patients received trimethoprim-sulphamethoxazole (TMP-SMX) 1,920 mg daily as a prophylaxis of Pneumocystis carinii infections and selective decontamination of gastrointestinal tract. The majority of patients received TMP-SMX in their first course of chemotherapy with daunorubicin and cytosine arabinoside. Only one of the 18 patients without TMP-SMX prophylaxis during the first course of chemotherapy developed Pneumocystis carinii pneumonia. That pneumonia was successfully treated by intravenous administration of TMP-SMX 1920 mg four times a day. No other Pneumocystis carinii infection was encountered in all other patients during their clinical follow up or in autopsy material of expired patients. TMP-SMX prophylaxis had to be interrupted in 11 patients due to their suspicious allergic skin reactions, however, TMP-SMX was readministered in all without any skin changes attributable to TMP-SMX during next cycles of chemotherapy. TMP-SMX in a given daily dose of 1,920 mg seems to be a successful prophylaxis of Pneumocystis carinii infections in patients with malignant diseases of hematopoiesis.
authors.affiliation: Ustav hematologie a krevní transfuze, Praha.
authors.forename: P
authors.initials: P
authors.lastname: Lemez
authors.forename: P
authors.initials: P
authors.lastname: Rysková
authors.forename: V
authors.initials: V
authors.lastname: Votava
authors.forename: M
authors.initials: M
authors.lastname: Suchmová
authors.forename: A
authors.initials: A
authors.lastname: Jirásek
authors.forename: I
authors.initials: I
authors.lastname: Rubík
mesh_terms: D000208:Acute Disease; D000328:Adult; D000754:Anemia, Refractory, with Excess of Blasts / Q000276:immunology*; D006801:Humans; D016867:Immunocompromised Host; D007951:Leukemia, Myeloid / Q000276:immunology*; D008297:Male; D009894:Opportunistic Infections / Q000517:prevention & control*; D011020:Pneumonia, Pneumocystis / Q000517:prevention & control*; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000008:administration & dosage*
chemical_list: D015662:Trimethoprim, Sulfamethoxazole Drug Combination
vernacular_title: Uspĕsná prevence infekce Pneumocystis carinii pomocí trimetoprim-sulfametoxazolu 1,920 mg dennĕ u nemocných se zhoubnými onemocnĕními krvetvorby.